|
KMID : 0191120200350430362
|
|
Journal of Korean Medical Science
2020 Volume.35 No. 43 p.362 ~ p.362
|
|
|
Serum Calprotectin Is a Potential Marker in Patients with Asthma
|
|
Lee Yun-Gi
Hong Ji-Su
Lee Pureun-Haneul
Lee June-Hyuk
Park Sung-Woo
Kim Do-Jin
Jang An-Soo
|
|
|
Abstract
|
|
|
Background: Calprotectin is the major cytosolic protein in neutrophil granulocytes. Although asthma is known to cause eosinophilic inflammation, some patients with asthma have non-eosinophilic inflammation, which is characterized by local neutrophilic inflammation. The aim of this study was to assess calprotectin expression levels in a mouse model of asthma, and to observe the relationship of serum calprotectin level and clinical variables in patients with asthma.
Methods: Mice were sensitized and challenged with 10 μg and 20 μg of Aspergillus fumigatus, respectively; mice treated with saline were used as a control. The levels of calprotectin were determined using enzyme-linked immunosorbent assay, immunoblotting, and immunohistochemical analysis. The serum levels of calprotectin were also assessed in patients with asthma. The relationship between calprotectin and clinicopathological characteristics was determined.
Results: Calprotectin, S100A8, and S100A9 expression was elevated in the mouse lungs, calprotectin levels were higher in the serum of patients with asthma (n = 33) compared with those of healthy individuals (n = 28). Calprotectin levels correlated with forced expiratory volume in one second/forced vital capacity (r = ?0.215, P = 0.043), smoke amount (r = 0.413, P = 0.017), body mass index (r = ?0.445, P = 0.000), and blood neutrophil percentage (r = 0.300, P = 0.004) in patients with asthma.
Conclusion: Our data suggest that calprotectin could potentially be used as a biomarker for asthma.
|
|
|
KEYWORD
|
|
|
Calprotectin, Asthma, Airway Inflammation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|